Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856863 | 0.92 | L3MBTL1 (0.39) | L3MBTL1HTTPOLBSMN1; SMN2MAPT | |
| SCHEMBL4855199 | 0.91 | ALDH1A1 (0.35) | L3MBTL1HTTALDH1A1MAPTLMNA | |
| SCHEMBL4853494 | 0.91 | L3MBTL1 (0.32) | L3MBTL1HTTSMN1; SMN2LMNA | |
| SCHEMBL5712076 | 0.91 | KMT2A (0.38) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4852580 | 0.90 | KMT2A (0.38) | L3MBTL1HTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4853708 | 0.89 | SLC6A4 (0.39) | ALDH1A1MAPTHPGD | |
| SCHEMBL4856627 | 0.82 | MEN1 (0.30) | — | |
| SCHEMBL4857423 | 0.82 | KMO (0.41) | L3MBTL1HTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4845948 | 0.81 | MAPT (0.43) | L3MBTL1HTTPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4845951 | 0.81 | MAPT (0.43) | L3MBTL1HTTPOLBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724275-B1 | PROCESS FOR PRODUCING AMINOPHOSPHONIC ACID DERIVATIVE | JAPAN SCIENCE & TECH AGENCY (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-7375244-B2 | Production method for aminophosphonic acid derivatives | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20070142658-A1 | Production method for aminophosphonic acid derivatives | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1724275-A1 | PROCESS FOR PRODUCING AMINOPHOSPHONIC ACID DERIVATIVE | Japan Science and Technology Agency (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142658-A1 | Production method for aminophosphonic acid derivatives | AASDHPPT, NPEPPS, DAO | L3MBTL1 2832/4885HTT 4618/4885POLB 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.